GALT — GALECTIN THERAPEUTICS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1133416 ·
Last close
$3.64
Market Cap
$367.09M
52W High
$7.13
52W Low
$2.03
ADV30
304,768
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,982,000 | -9,113,000 | 14,826,000 | 13,269,000 | 151,678,000 |
| Mar 2026 | 0 | — | -4,077,000 | -5,046,000 | 15,759,000 | 14,111,000 | 145,996,000 |
| Dec 2025 | 0 | — | -3,365,000 | -5,500,000 | 19,532,000 | 17,720,000 | 145,727,000 |
| Sep 2025 | 0 | — | -4,198,000 | -8,184,000 | 12,865,000 | 11,525,000 | 138,168,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,052,000
Investing CF
—
Financing CF
$26,732,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.48
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-437,613,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-18,678,000
Pretax Income TTM
$-26,251,000
Interest Exp TTM
$7,573,000
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -20,085,000 | -30,836,000 | 19,532,000 | 145,727,000 | -126,195,000 | -23,875,000 |
| Dec 2024 | 0 | -42,433,000 | -47,047,000 | 17,495,000 | 120,565,000 | -103,070,000 | -41,767,000 |
| Dec 2023 | 0 | -38,072,000 | -41,066,000 | 28,200,000 | 88,441,000 | -60,241,000 | -32,965,000 |
| Dec 2022 | 0 | -38,352,000 | -38,776,000 | 21,285,000 | 53,479,000 | -32,194,000 | -31,056,000 |
TTM Snapshot
Revenues TTM
$127,000
NetIncome TTM
$-26,251,000
OpCashFlow TTM
—
Assets (Latest)
$15,759,000
Forward EPS
$-1.68
Max Pain — expiry 2026-10-16
max pain strike: $5.00 · spot: $3.94 · call oi: 3,976 · put oi: 2,699
Expected Move to 2026-10-16:
±$1.00
(25.38%) —
implied range
$2.94 –
$4.94
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARCT | Arcturus Therapeutics Holdings Inc. | $365.80M | $12.87 | — |
| PTCHF | PureTech Health plc | $370.22M | $1.51 | — |
| IRD | Opus Genetics, Inc. | $371.05M | $4.46 | — |
| ENTA | ENANTA PHARMACEUTICALS INC | $352.42M | $12.10 | — |
| EBS | Emergent BioSolutions Inc. | $349.17M | $6.81 | — |
News headlines (Yahoo Finance, 1h cache)
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
2026-10-06 12:00 · Yahoo
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 12:00 · Yahoo
Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight
2026-08-24 14:31 · Yahoo
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
2026-08-14 12:00 · Yahoo
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
2026-08-04 12:00 · Yahoo
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
2026-06-23 12:00 · Yahoo
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
2026-05-27 12:00 · Yahoo
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
2026-05-11 12:00 · Yahoo
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?
2026-04-03 16:00 · Yahoo
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
2026-03-31 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.